Comparative Pharmacology
Head-to-head clinical analysis: NORINYL versus NORINYL 1 35 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL versus NORINYL 1 35 28 DAY.
NORINYL vs NORINYL 1+35 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) provides contraception by inhibiting gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Norethindrone is a progestogen that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation and altering cervical mucus and endometrial thickness.
One tablet (norethindrone 1 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 placebo tablets. For first cycle, start on first Sunday after menstruation begins or on day 1 of menstrual cycle.
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 inert tablets).
None Documented
None Documented
Terminal half-life: norethindrone 7-8 hours, ethinyl estradiol 13-27 hours; clinical context: steady-state achieved in 3-5 half-lives
Norethindrone: 7-8 hours (terminal half-life); steady state achieved after 5 days. Ethinyl estradiol: biphasic with terminal half-life of 13-27 hours (mean ~17 hours). Clinical context: dosing interval of 24 hours allows stable hormone levels after first cycle.
Renal: ~60% as metabolites, biliary/fecal: ~40% as glucuronide conjugates
Renal: 50-60% (conjugates and metabolites), Fecal: 30-40% (biliary elimination of norethindrone and ethinyl estradiol conjugates); total clearance ~4-6 mL/min/kg.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive